Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Mon, Dec 2, 2024
[Archive]
Volume 14, Issue 1 (Winter 2023)
Caspian J Intern Med 2023, 14(1): 1-9 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharifi M, Farajzadegan Z, Rezaei Jouzdani S. A systematic review evaluating the efficacy of autologous hematopoietic transplantation for diffuse large B cell lymphoma-type Richter syndrome. Caspian J Intern Med 2023; 14 (1) :1-9
URL: http://caspjim.com/article-1-3391-en.html
URL: http://caspjim.com/article-1-3391-en.html
Department of Internal Medicine , school of medicine , Cancer prevention Research Center , Seyyed Al-Shohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran , s.rezaei.jouzdani@gmail.com
Abstract: (2494 Views)
Background: Chronic lymphocytic leukemia (CLL) can transform into fast growing lymphoma for diffuse large B-cell lymphoma (DLBCL) called Richter's syndrome (RS), which is commonly related to an existence of large B-cells with equal or larger size than macrophage nuclei or more than twice those of normal lymphocyte. We conducted a systematic review of the existing literature to assess the clinical efficacy of auto-HCT for patients with RS.
Methods: We searched 4 main databases; EMBASE, Google Scholar, Scopus, PubMed and Web of Science and was done on December 26,2021. All analyses in this study were performed by Stata software and this review was reported in accordance with PRISMA 2020.
Results: Data was extracted from 4 articles; the total number of patients was reported to be 110. Based on the meta-analysis findings, pooled overall survival rate was 56.36% (95%CI= (46.98 – 65.31). In figure 2, the forest plot of combined results is shown.
Conclusion: Despite the use of common treatment regimens such as chemo immunotherapy and the availability of novel therapies including B-cell receptor inhibitors and rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone (CHOP-R) regimen, the status of disease progression and recovery in RS cases is still not strong enough.
Methods: We searched 4 main databases; EMBASE, Google Scholar, Scopus, PubMed and Web of Science and was done on December 26,2021. All analyses in this study were performed by Stata software and this review was reported in accordance with PRISMA 2020.
Results: Data was extracted from 4 articles; the total number of patients was reported to be 110. Based on the meta-analysis findings, pooled overall survival rate was 56.36% (95%CI= (46.98 – 65.31). In figure 2, the forest plot of combined results is shown.
Conclusion: Despite the use of common treatment regimens such as chemo immunotherapy and the availability of novel therapies including B-cell receptor inhibitors and rituximab-cyclophosphamide-hydroxydaunorubicin-Oncovin-prednisone (CHOP-R) regimen, the status of disease progression and recovery in RS cases is still not strong enough.
Type of Study: Review Article |
Subject:
Hematology
Received: 2022/02/25 | Accepted: 2022/06/18 | Published: 2023/01/11
Received: 2022/02/25 | Accepted: 2022/06/18 | Published: 2023/01/11
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
